TEM: AI-driven data and diagnostics, FDA approvals, and strategic deals fuel 25%+ growth outlook
Strong diagnostic and data businesses are driving robust growth, with FDA approvals and pricing upgrades set to deliver significant revenue and margin expansion. Strategic acquisitions and AI-driven data licensing position the company for sustained 25%+ growth, while durable reimbursement and a com…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.